Efficacy and safety of zoledronic acid in the treatment of glucocorticoid-induced osteoporosis

Review

(1943) Views  (763) Full article downloads

Authors: Ege Can Serefoglu, Zafer Tandogdu

Published Date May 2010 Volume 2010:6 Pages 219 - 223

DOI: http://dx.doi.org/10.2147/TCRM.S7245

Ege Can Serefoglu¹, Zafer Tandogdu²

¹Kiziltepe Hospital, Department of Urology, Mardin, Turkey; ²Taksim Teaching Hospital, Department of Urology, Istanbul, Turkey

Abstract: Glucocorticoids are essential in treating many disorders and they are widely used in spite of their negative impact on the skeletal system. As bisphosphonates reduce bone resorption through their action on osteoclasts, they play an important role in management of glucocorticoid-induced osteoporosis. Unlike other bisphosphonates, zoledronic acid is given by intravenous infusion and it has a potential advantage of increasing the compliance and adherence of patients when it is given 5 mg once a year. However, this treatment modality seems to be associated with more adverse events than oral administrations, and further studies with longer follow-up periods must be conducted to determine the safety and cost-effectiveness of long-term treatment with zoledronic acid.

Keywords: bisphosphonates, glucocorticoids, osteoporosis, zoledronic acid